LPC
TGTX icon

Lion Point Capital’s TG Therapeutics TGTX Stock Holding History

Lion Point Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,160,307
Closed -$22M – 37
2021
Q4 		$22M Buy
1,160,307
+321,179
+38% +$8.34M 5.91% 6
2021
Q3 		$27.9M Buy
839,128
+230,000
+38% +$7.12M 5.24% 6
2021
Q2 		$23.6M Hold
609,128
– – 4.08% 10
2021
Q1 		$29.4M Sell
609,128
-718,606
-54% -$34.5M 5.34% 9
2020
Q4 		$69.1M Hold
1,327,734
– – 13.3% 1
2020
Q3 		$35.5M Buy
1,327,734
+429,935
+48% +$9.89M 7.79% 3
2020
Q2 		$17.5M Buy
+897,799
New +$14.5M 4.24% 10

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Lion Point Capital's TGTX Position: Q1 2022 in Review

Lion Point Capital sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 1,160,307 shares — an estimated $22M sold.

Lion Point Capital first reported a position in TGTX in Q2 2020 and held it in 7 quarters. The position peaked at $69.1M in Q4 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

  • Lion Point Capital reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Lion Point Capital sold 1,160,307 TG Therapeutics shares in Q1 2022, an estimated $22M.
  • Lion Point Capital first reported a position in TG Therapeutics in Q2 2020 and held it in 7 quarters.
  • Lion Point Capital's TG Therapeutics position peaked at $69.1M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Lion Point Capital's 13F filing for Q1 2022, filed 16 May 2022.